NNVC Looks Poised for Transformative Growth as Zacks Highlights NV-387's Broad-Spectrum Antiviral Potential Across Biodefense and Global Viral Threats. Zacks Has Issued a $7 Valuation! NanoViricides (NYSE: NNVC) is capturing investor attention as the company's leading drug candidate NV-387 prepares to enter Phase 2 clinical trials for MPox, a strategic step toward addressing both emerging viral threats and biodefense needs. NV-387's novel nanoviricide technology not only neutralizes viruses before infection but also protects critical organs like the lungs, offering a unique therapeutic advantage over conventional antivirals. Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-387's utility across measles, influenza, RSV, and coronaviruses — a potential multi-billion-dollar antiviral market. With a $7 valuation, Zacks Small Cap Research underscores NNVC's promising outlook, emphasizing NV-387's potential for strategic government procurement, orphan drug exclusivity, and BARDA funding. NNVC's Phase 1 safety data, broad preclinical efficacy, and advanced clinical planning suggest an asymmetric upside for investors. With trials imminent and a clear path to regulatory milestones, NNVC stands ready to redefine antiviral therapy. Positive results from the company's Phase 2 clinical trials for MPox could have immediate implications for FDA approval under the Animal Rule for Smallpox, unlocking a $1 billion market via the U.S. Strategic National Stockpile and potential BARDA funding — a major milestone for shareholder value! See how NNVC is gearing up to transform the antiviral landscape while catching Wall Street attentionToday's editorial pick for you The Dogs of the Dow: A Year-End Dividend OpportunityPosted On Nov 21, 2025 by Chris Markoch  One of the best year-end investment strategies is the Dogs of the Dow. Granted, some analysts say it's an antiquated strategy with low success rates. But history proves they still have plenty of bite. Table of ContentsIn fact, having traded the Dogs of the Dow since 2016, I can tell you it's still a solid strategy with dividend payouts to boot. For those of you who are new to the Dogs, it's one of the easiest – and oftentimes most profitable strategies. You simply buy a basket of underperformers on the Dow that pay dividends, and sell by the end of the year. In most years, the Dogs do pretty well. What makes the strategy attractive is that you're buying the highest-yielding stocks on the Dow, which itself is made up of large, established, and financially stable companies. This selection process filters for reliability and lowers the risk of investing in a speculative venture. All you’re really doing is investing in temporarily beaten-down respected companies and collecting yield until the stock decides to rally back. For those who are new to the Dogs of the Dow, it really is that easy. A Proven Track RecordLet's look at how the Dogs have done historically since 2016. The 2024 Dogs of the Dow underperformed the major indices in 2024. However, with dividends, investors still did well for the year. The 2023 Dogs of the Dow returned an average of 10.1%, which came in below the 14.4% return on the Dow Jones Industrials. Still, with the appreciation in most of the 2023 Dogs coupled with dividends, investors still did well overall. The 2022 Dogs of the Dow beat the major indices, even in a rough year. In fact, while the Dogs of the Dow stocks fell 1.6% on the year, once you add in the dividend payouts, the Dogs returned 2% on the year. And while 2% may not sound like a big win, consider that, in 2022, one of the worst years on record since 2008, the NASDAQ lost 33%. The S&P 500 lost 19%. The Dow Jones lost about 9%. In 2021, the Dogs of the Dow returned about 16.3%. While 2020 wasn't a great year for the Dogs, most other years have done very well. In 2019, the Dogs were up 20%. In 2018, they were up about 1%, but still beat the Dow, which fell close to 6%. In 2017, the dogs were up 19%. In 2016, they were up 16%. How Are the Dogs of the Dow Doing in 2025?For 2025, here's how the Dogs are doing.
Eight out of 10 isn't bad at all. ConclusionNot only do investors make a substantial amount of money year to date from the Dogs of the Dow stocks, but they also earn a good return on the dividends. Also, while the 2026 Dogs of the Dow list hasn’t been released yet, stay tuned. We’ll share that list with you once it’s officially out. This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $4000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 01, 2025 and Dec 05, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on EQUISCREEN, LLC website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC). StockEarnings, Inc |
0 Response to "👉 Phase 2 Trials Incoming - Could NNVC Be the Next Biotech Giant?"
Post a Comment